Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases.
J Dermatol
; 50(7): 912-916, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-36938650
ABSTRACT
Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane-switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second-line chemotherapy were evaluated retrospectively in 50 Japanese taxane-resistant CAS patients. Although there was no significant difference in progression-free survival (P = 0.3528) among the regimens, the incidence of all adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane-switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane-resistant CAS in second-line therapy based on the safety profiles.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Hemangiosarcoma
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
J Dermatol
Año:
2023
Tipo del documento:
Article